Lung-Targeting Lysostaphin Microspheres for Methicillin-Resistant Staphylococcus aureus Pneumonia Treatment and Prevention. 2021

Xiuhui Lin, and Jian He, and Wanlin Li, and Yuchen Qi, and Huiqun Hu, and Dongxiao Zhang, and Feng Xu, and Xiaoyuan Chen, and Min Zhou
Department of Infectious Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.

Multifunctional antimicrobial strategies are urgently needed to treat methicillin-resistant Staphylococcus aureus (MRSA) caused pneumonia due to its increasing resistance, enhanced virulence, and high pathogenicity. Here, we report that lysostaphin, a bacteriolytic enzyme, encapsulated within poly(lactic-co-glycolic acid) microspheres (LyIR@MS) specially treats planktonic MRSA bacteria, mature biofilms, and related pneumonia. Optimized LyIR@MS with suitable diameters could deliver a sufficient amount of lysostaphin to the lung without a decrease in survival rate after intravenous injection. Furthermore, the degradable properties of the carrier make it safe for targeted release of lysostaphin to eliminate MRSA, repressing the expression of virulence genes and improving the sensitivity of biofilms to host neutrophils. In the MRSA pneumonia mouse model, treatment or prophylaxis with LyIR@MS significantly improved survival rate and relieved inflammatory injury without introducing adverse events. These findings suggest the clinical translational potential of LyIR@MS for the treatment of MRSA-infected lung diseases.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008248 Lysostaphin A 25-kDa peptidase produced by Staphylococcus simulans which cleaves a glycine-glcyine bond unique to an inter-peptide cross-bridge of the STAPHYLOCOCCUS AUREUS cell wall.
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008863 Microspheres Small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various reagents acting as tags or markers. Latex Beads,Latex Particles,Latex Spheres,Microbeads,Bead, Latex,Beads, Latex,Latex Bead,Latex Particle,Latex Sphere,Microbead,Microsphere,Particle, Latex,Particles, Latex,Sphere, Latex,Spheres, Latex
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013203 Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS. Infections, Staphylococcal,Staphylococcus aureus Infection,Staphylococcal Infection,Staphylococcus aureus Infections
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D055624 Methicillin-Resistant Staphylococcus aureus A strain of Staphylococcus aureus that is non-susceptible to the action of METHICILLIN. The mechanism of resistance usually involves modification of normal or the presence of acquired PENICILLIN BINDING PROTEINS. MRSA,Methicillin Resistant Staphylococcus aureus
D018441 Biofilms Encrustations formed from microbes (bacteria, algae, fungi, plankton, or protozoa) embedded in an EXTRACELLULAR POLYMERIC SUBSTANCE MATRIX that is secreted by the microbes. They occur on body surfaces such as teeth (DENTAL DEPOSITS); inanimate objects, and bodies of water. Biofilms are prevented from forming by treating surfaces with DENTIFRICES; DISINFECTANTS; ANTI-INFECTIVE AGENTS; and anti-fouling agents. Biofilm

Related Publications

Xiuhui Lin, and Jian He, and Wanlin Li, and Yuchen Qi, and Huiqun Hu, and Dongxiao Zhang, and Feng Xu, and Xiaoyuan Chen, and Min Zhou
January 2014, BioMed research international,
Xiuhui Lin, and Jian He, and Wanlin Li, and Yuchen Qi, and Huiqun Hu, and Dongxiao Zhang, and Feng Xu, and Xiaoyuan Chen, and Min Zhou
May 1989, Journal of clinical microbiology,
Xiuhui Lin, and Jian He, and Wanlin Li, and Yuchen Qi, and Huiqun Hu, and Dongxiao Zhang, and Feng Xu, and Xiaoyuan Chen, and Min Zhou
May 2000, Investigative ophthalmology & visual science,
Xiuhui Lin, and Jian He, and Wanlin Li, and Yuchen Qi, and Huiqun Hu, and Dongxiao Zhang, and Feng Xu, and Xiaoyuan Chen, and Min Zhou
June 1998, Antimicrobial agents and chemotherapy,
Xiuhui Lin, and Jian He, and Wanlin Li, and Yuchen Qi, and Huiqun Hu, and Dongxiao Zhang, and Feng Xu, and Xiaoyuan Chen, and Min Zhou
October 2000, American journal of ophthalmology,
Xiuhui Lin, and Jian He, and Wanlin Li, and Yuchen Qi, and Huiqun Hu, and Dongxiao Zhang, and Feng Xu, and Xiaoyuan Chen, and Min Zhou
April 2009, Pediatric research,
Xiuhui Lin, and Jian He, and Wanlin Li, and Yuchen Qi, and Huiqun Hu, and Dongxiao Zhang, and Feng Xu, and Xiaoyuan Chen, and Min Zhou
July 2012, Chest,
Xiuhui Lin, and Jian He, and Wanlin Li, and Yuchen Qi, and Huiqun Hu, and Dongxiao Zhang, and Feng Xu, and Xiaoyuan Chen, and Min Zhou
October 2005, Emerging infectious diseases,
Xiuhui Lin, and Jian He, and Wanlin Li, and Yuchen Qi, and Huiqun Hu, and Dongxiao Zhang, and Feng Xu, and Xiaoyuan Chen, and Min Zhou
December 2008, Disease-a-month : DM,
Xiuhui Lin, and Jian He, and Wanlin Li, and Yuchen Qi, and Huiqun Hu, and Dongxiao Zhang, and Feng Xu, and Xiaoyuan Chen, and Min Zhou
December 2012, The Annals of pharmacotherapy,
Copied contents to your clipboard!